What Does Elicio Therapeutics Do?

Total employees43
HeadquartersCambridge
Founded

Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company dedicated to developing a new class of potent immunotherapies. Their proprietary Amphiphile (AMP) platform is designed to deliver immunogens, including checkpoint agonists, and adjuvants directly to the lymph nodes. This targeted delivery aims to enhance the body's immune response, particularly T cell activity, to fight cancers and other diseases. Elicio's pipeline includes ELI-002, an AMP-KRAS vaccine for KRAS-driven cancers currently in clinical trials, as well as other candidates targeting various mutations and diseases.

Where Is Elicio Therapeutics's Headquarters?

HQ Function

Primary hub for research and development, corporate operations, and strategic management.

Notable Features:

Located within the One Kendall Square complex, a prominent center for life science and technology companies, offering modern laboratory and office facilities.

Work Culture:

A dynamic, innovative, and science-driven environment focused on collaboration and advancing groundbreaking immunotherapies. Employees are typically mission-oriented, working towards developing treatments for serious diseases.

HQ Significance:

Kendall Square in Cambridge is a leading global biotechnology hub, providing Elicio Therapeutics with access to a rich ecosystem of talent, research institutions (like MIT and Harvard), potential partners, and investors.

Values Reflected in HQ: The headquarters' location in a premier biotech hub reflects Elicio's commitment to cutting-edge science, innovation, and collaboration within the life sciences community.

Location:

Elicio Therapeutics is primarily based in the United States, with its research, development, and corporate operations headquartered in Cambridge, MA. While its core R&D and administrative functions are U.S.-centric, the company's clinical trials for its therapeutic candidates, such as ELI-002, are conducted at sites in multiple countries. This gives Elicio an operational reach for its clinical development programs beyond the U.S., engaging with international medical centers and patient populations.

Street Address:

One Kendall Square, Suite B14202

City:

Cambridge

State/Province:

MA

Country:

United States

Where Else Does Elicio Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Elicio Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Elicio Therapeutics? Meet the Executive Team

As of April 2025, Elicio Therapeutics' leadership includes:

Robert Connelly - Chief Executive Officer
Christopher Haqq, M.D., Ph.D. - Executive Vice President, Head of Research and Development, and Chief Medical Officer
Kashif M. Rathore - Chief Financial Officer
Annette Matthies, Ph.D. - Chief Business Officer
Erin Lavelle - Chief Operating Officer and General Counsel

Who's Investing in Elicio Therapeutics?

Elicio Therapeutics has been backed by several prominent investors over the years, including:

Clal Biotechnology Industries Ltd.
Entities affiliated with Gordian Ventures (IGSB)
Various institutional and retail investors (as a publicly traded company)
Access Bridge Ventures (early investor)
Omega Funds (early investor)

What Leadership Changes Has Elicio Therapeutics Seen Recently?

Hire1
Exits1

Elicio Therapeutics strengthened its executive team over the past year with a key appointment in its financial leadership, following a planned transition. These changes support the company's progression through clinical development and strategic growth.

Departures

Lisa M. Caperelli, Lisa M. Caperelli stepped down as Chief Financial Officer.

New Appointments:

Kashif M. Rathore, Kashif M. Rathore was appointed as Chief Financial Officer, succeeding the interim CFO.

What Technology (Tech Stack) Is Used byElicio Therapeutics?

Discover the tools Elicio Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Elicio Therapeutics Email Formats and Examples

Elicio Therapeutics primarily uses the [first_initial][last]@elicio.com email format for its employees. Variations may exist, but this is the most commonly observed pattern.

[first_initial][last]@elicio.com

Format

jdoe@elicio.com

Example

85%

Success rate

What's the Latest News About Elicio Therapeutics?

Business WireMay 20, 2024

Elicio Therapeutics Announces ELI-002 Phase 1 (AMPLIFY-201) Study Published in Nature Medicine

Elicio Therapeutics announced that results from its Phase 1 AMPLIFY-201 study of ELI-002 were published in Nature Medicine. The study showed ELI-002, an investigational therapeutic vaccine, induced robust T cell responses and anti-tumor effects in patients with KRAS-mutated solid tumors....more

GlobeNewswireMay 14, 2024

Elicio Therapeutics Provides Business Highlights and Reports First Quarter 2024 Financial Results

Elicio Therapeutics reported its financial results for the first quarter of 2024 and provided updates on its clinical programs, including advancements with ELI-002 and other pipeline candidates targeting mKRAS-driven cancers....more

GlobeNewswireApril 2, 2024

Elicio Therapeutics Announces First Patient Dosed in Relapsed/Refractory KRAS/NRAS Mutated Solid Tumor Cohort of Phase 1a Study (AMPLIFY-7P) Evaluating ELI-007

Elicio announced the dosing of the first patient in its Phase 1a AMPLIFY-7P study evaluating ELI-007, an AMP-modified CpG adjuvant combined with other anti-cancer agents, for patients with relapsed/refractory KRAS/NRAS mutated solid tumors....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Elicio Therapeutics, are just a search away.